

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212

Provisional Stakeholder List


Consultees	Commentators (no right to submit or
	appeal)
 Company GlaxoSmithKline (belantamab mafodotin) Patient/carer groups African Caribbean Leukaemia Trust Anthony Nolan Black Health Agency for Equality Blood Cancer UK Cancer Black Care Cancer Equality 	General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland
 Cancer52 DKMS Helen Rollason Cancer Charity Independent Cancer Patients Voice Kevin Karawa Leukaemia Trust Leukaemia Cancer Society Leukaemia Care Macmillan Cancer Support Maggie's Centres Marie Curie 	 Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Myeloma UK South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care 	 Possible comparator companies AbbVie (dexamethasone) ADVANZ Pharma (dexamethasone, lenalidomide) Amarox (lenalidomide)
 Healthcare professional groups Association of Cancer Physicians British Blood Transfusion Society British Committee for Standards in Haematology British Geriatrics Society British Institute of Radiology British Oncology Pharmacy 	 Amgen (carfilzomib) AS Kalceks (dexamethasone) Aspen (dexamethasone) Aspire Pharma (bortezomib, dexamethasone) Aurobindo Pharma (bortezomib) Bausch & Lomb U.K (dexamethasone) Biocon Pharma UK (lenalidomide)

Provisional stakeholder list for evaluation of belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212 Issue date: January 2024



Consultees Commentators (no right to submit or appeal) Association **Bristol Myers Squibb Pharmaceuticals** British Psychosocial Oncology Society (lenalidomide, pomalidomide) British Society for Haematology Dr. Reddy's Laboratories UK (bortezomib) **British Society of Interventional** Radiology Glenmark Pharmaceuticals Europe **British Transplantation Society** (dexamethasone, lenalidomide) Hameln pharma (dexamethasone) Cancer Research UK NHS Blood and Transplant Hospira UK (dexamethasone) Janssen-Cilag (bortezomib, Royal College of General Practitioners daratumumab, ciltacabtagene Royal College of Nursing autoleucel) Royal College of Pathologists Krka UK (dexamethasone) Royal College of Physicians Martindale Pharma, an Ethypharm Royal College of Radiologists Group Company (dexamethasone) Royal Pharmaceutical Society Medac GmbH (bortezomib) Royal Society of Medicine Menarini Stemline UK (selinexor) Society and College of Radiographers MSN Laboratories Europe (bortezomib) **UK Clinical Pharmacy Association** Mylan (bortezomib. lenalidomide) UK Myeloma Society Novartis Pharmaceuticals UK **UK Oncology Nursing Society** (dexamethasone) Panpharma UK (dexamethasone) **Others** ParaPharm Development Department of Health and Social Care (dexamethasone) NHS England • Pfizer (bortezomib, elranatamab) • Piramal Critical Care (lenalidomide) Ranbaxy UK Limited a Sun Pharmaceutical Company (bortezomib, lenalidomide) Rayner Pharmaceuticals (dexamethasone) Rosemont Pharmaceuticals (dexamethasone) • Sandoz (bortezomib, lenalidomide) • Sanofi (dexamethasone, isatuximab) • Santen UK (dexamethasone) Synchrony Pharma (dexamethasone) Takeda UK (ixazomib) Teva UK (dexamethasone, lenalidomide) Thame Laboratories (dexamethasone) Thea Pharmaceuticals (dexamethasone) Thornton & Ross (bortezomib, lenalidomide)

Provisional stakeholder list for evaluation of belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212 Issue date: January 2024



Consultees	Commentators (no right to submit or appeal)
	 Tillomed Laboratories (bortezomib) Wockhardt UK (dexamethasone) Zentiva (bortezomib, lenalidomide) ZR Pharma & GmBH (panobinostat)
	 Relevant research groups Cochrane Haematological Malignancies Group Cochrane UK Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK MRC Clinical Trials Unit National Institute for Health Research
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees


Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Provisional stakeholder list for evaluation of belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212 Issue date: January 2024



Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.